Delayed
OTC Markets
20:59:37 22/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.0185
USD
|
-25.25%
|
|
-25.40%
|
-51.19%
|
Fiscal Period: Juni |
2023
|
---|
Capitalization
1 |
3.02
|
Enterprise Value (EV)
1 |
3.494
|
P/E ratio
|
-16.6
x
|
Yield
|
-
|
Capitalization / Revenue
|
258,223,153
x
|
EV / Revenue
|
298,725,376
x
|
EV / EBITDA
|
-
|
EV / FCF
|
-165,063,164
x
|
FCF Yield
|
-0%
|
Price to Book
|
-8.77
x
|
Nbr of stocks (in thousands)
|
10,418
|
Reference price
2 |
0.2899
|
Announcement Date
|
04/08/23
|
Fiscal Period: Juni |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.004052
|
0.0117
|
0.0117
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.039
|
-0.0821
|
-0.0545
|
-0.1464
|
Operating Margin
|
-
|
-2,027.07%
|
-465.72%
|
-1,251.48%
|
Earnings before Tax (EBT)
1 |
-0.0463
|
-0.0805
|
-0.2453
|
-0.1803
|
Net income
1 |
-0.0463
|
-0.1018
|
-0.2453
|
-0.1803
|
Net margin
|
-
|
-2,513.47%
|
-2,096.98%
|
-1,541.59%
|
EPS
|
-
|
-0.0101
|
-0.0236
|
-0.0175
|
Free Cash Flow
|
-
|
-0.026
|
-0.0395
|
-0.0212
|
FCF margin
|
-
|
-641.19%
|
-337.97%
|
-180.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
07/10/20
|
22/07/22
|
22/07/22
|
04/08/23
|
Fiscal Period: June |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.01
|
-
|
0.07
|
0.47
|
Net Cash position
1 |
-
|
0.01
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-0.03
|
-0.04
|
-0.02
|
ROE (net income / shareholders' equity)
|
-
|
2,756%
|
193%
|
60%
|
ROA (Net income/ Total Assets)
|
-
|
-49.3%
|
-24.7%
|
-45%
|
Assets
1 |
-
|
0.2064
|
0.9939
|
0.4009
|
Book Value Per Share
2 |
-0
|
-0
|
-0.0200
|
-0.0300
|
Cash Flow per Share
2 |
0
|
0
|
0.0100
|
0
|
Capex
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
Announcement Date
|
07/10/20
|
22/07/22
|
22/07/22
|
04/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -51.19% | 196K | | +9.28% | 8.74B | | -14.24% | 4.94B | | +49.95% | 4.7B | | +5.96% | 3.98B | | -23.57% | 2.28B | | +12.07% | 2.28B | | +16.45% | 2.14B | | -33.59% | 2.12B | | -0.50% | 1.64B |
Specialty & Advanced Pharmaceuticals
|